Statement of Changes in Beneficial Ownership (4)
December 17 2014 - 4:37PM
Edgar (US Regulatory)
CONFIRMING STATEMENT
This statement confirms that the undersigned has authorized and designated
the Chief Executive Officer, the Chief Financial Officer or the Chief Operating
Officer of Galectin Therapeutics Inc. (the "Company") to execute and file on the
undersigned's behalf all Forms 3, 4 and 5 (including any amendments thereto)
that the undersigned may be required to file with the U.S. Securities and
Exchange Commission as a result of the undersigned's ownership of or
transactions in securities of the Company. The authority of the Chief
Executive Officer, the Chief Financial Officer or the Chief Operating Officer of
the Company under this Statement shall continue until the undersigned is no
longer required to file Forms 3, 4 and 5 with regard to the undersigned's
ownership of or transactions in securities of the Company unless earlier revoked
in writing. The undersigned acknowledges that the Chief Executive Officer,
the Chief Financial Officer or the Chief Operating Officer of the Company is not
assuming any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934.
Dated as of July 1, 2013 |
/s/ Gilbert F. Amelio
Name: Gilbert F. Amelio |
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2023 to Sep 2024